PPARG

Chr 3ADARMulti

peroxisome proliferator activated receptor gamma

Also known as: CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2, PPARG5, PPARgamma

The protein is a ligand-activated transcription factor that regulates adipocyte differentiation, lipid metabolism, and glucose homeostasis by forming heterodimers with retinoid X receptors and binding to specific DNA response elements. Mutations cause familial partial lipodystrophy type 3, severe insulin resistance, type 2 diabetes, and severe obesity, affecting metabolic regulation throughout life. Inheritance patterns include autosomal dominant, autosomal recessive, and multifactorial depending on the specific condition.

OMIMResearchSummary from RefSeq, OMIM, UniProt
DNmechanismAD/AR/MultiLOEUF 0.644 OMIM phenotypes
Clinical SummaryPPARG
🧬
Gene-Disease Validity (ClinGen)
lipodystrophy · SDDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.32) despite low pLI — interpret in context.
📋
ClinVar Variants
57 unique Pathogenic / Likely Pathogenic· 121 VUS of 297 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.64LOEUF
pLI 0.029
Z-score 2.71
OE 0.32 (0.170.64)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
2.12Z-score
OE missense 0.65 (0.570.73)
183 obs / 283.4 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios
LoF OE0.32 (0.170.64)
00.351.4
Missense OE0.65 (0.570.73)
00.61.4
Synonymous OE1.01
01.21.6
LoF obs/exp: 6 / 18.6Missense obs/exp: 183 / 283.4Syn Z: -0.06
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitivePPARG-related lipodystrophy, familial partialDNAD
definitivePPARG-related acanthosis nigricans with insulin resistance syndrome and hypertensionDNAD
DN
0.7229th %ile
GOF
0.6052th %ile
LOF
0.4136th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median · 1 literature citation
LOF26% of P/LP variants are LoF

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

DNConsistent with this, both receptor mutants are markedly transcriptionally impaired and, moreover, are able to inhibit the action of coexpressed wild-type PPARgamma in a dominant negative manner.PMID:10622252

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

297 submitted variants in ClinVar

Classification Summary

Pathogenic35
Likely Pathogenic22
VUS121
Likely Benign81
Benign15
Conflicting11
35
Pathogenic
22
Likely Pathogenic
121
VUS
81
Likely Benign
15
Benign
11
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
7
3
25
0
35
Likely Pathogenic
8
13
1
0
22
VUS
2
113
4
2
121
Likely Benign
0
8
22
51
81
Benign
0
0
11
4
15
Conflicting
11
Total171376357285

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PPARG · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Alzheimer's Disease

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

NOT YET RECRUITING
NCT06964230Phase PHASE2, PHASE3T3D Therapeutics, Inc.Started 2026-10-26
T3D-959Placebo Comparator
Long COVIDInsulin ResistanceInsulin Sensitivity

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

RECRUITING
NCT05833217Phase NAStanford UniversityStarted 2023-06-06
Adipose Tissue BiopsySteady State Plasma Glucose (SSPG) Test
Lipodystrophy (Genetic or Acquired, Non HIV)

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

RECRUITING
NCT03087253University of MichiganStarted 2018-02-27
HIV-1-infection

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

RECRUITING
NCT06203132Phase PHASE3ANRS, Emerging Infectious DiseasesStarted 2025-01-27
Doravirine + tenofovir DF + lamivudineDolutegravir + tenofovir DF + lamivudine or emtricitabine
Cancer

Onco Move - Improvement of Psychophysical Fitness in Adult Cancer Survivors

NOT YET RECRUITING
NCT07087652Phase NAGdansk University of Physical Education and SportStarted 2025-09-01
Onco Move multicomponent face-to-face training program
Obesity and Obesity-related Medical Conditions

Precision Nutrition Technologies for Obesity Management

NOT YET RECRUITING
NCT07101133Phase NAYuan HeStarted 2025-07-27
Control group: Energy-limited balanced diet group
Hereditary Pulmonary Alveolar Proteinosis

Safety and Efficacy of PMT Therapy of hPAP

RECRUITING
NCT05761899Phase PHASE1, PHASE2Children's Hospital Medical Center, CincinnatiStarted 2023-06-26
Gene-Corrected Macrophages administered by bronchoscopic instillation
GenomicsThyroid CancerNGS

Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk Stratification and Post-Treatment Surveillance in Fresh Thyroid Cancer Patients

NOT YET RECRUITING
NCT07532356National Taiwan University HospitalStarted 2026-08-01
Nonalcoholic SteatohepatitisLiver Fibrosis

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

RECRUITING
NCT05526144Phase PHASE2VA Office of Research and DevelopmentStarted 2023-04-01
SynthroidPlacebo
ANCA Associated VasculitisExtramembranous GlomerulopathyNephrotic Syndrome, Minimal Change

Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis

NOT YET RECRUITING
NCT07010250Assistance Publique - Hôpitaux de ParisStarted 2025-06-02
Maternal ObesityObesity

The Developmental Origins of Obesity

RECRUITING
NCT06981676Phase NAPontificia Universidad Catolica de ChileStarted 2023-07-25
DHA and EPA
Morbid ObesityBariatric SurgeryTelerehabilitation

Exercise to Fight Obesity

RECRUITING
NCT06934681Phase NAInstituto de Investigacion Sanitaria La FeStarted 2025-05-19
Usual Care GroupControlled exercise with telerehabilitation
Clinical Literature
Open Research Assistant →